AFP, Paris :
French pharma giant Sanofi said Tuesday it had signed a billion-dollar deal to buy US-based biotech firm Amunix, which develops cancer treatments that enlist the body’s immune system. “Sanofi will acquire Amunix for an upfront payment of approximately $1 billion (890 million euros) and up to $225 million upon achievement of certain future development milestones,” the French firm said in a statement. Immuno-oncology firm Amunix is developing cancer therapies based on cytokines — small proteins that play a role in controlling the immune system — and T-cells, a type of white blood cell.
